[6,6] Fused bicyclic HDAC8 inhibitors
The present invention is directed to compounds of Formula I: and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers or thereof, wherein R 1 , R 2 , R 2 ′, L, X, W, Y 1 , Y 2 , Y 3 , and Y 4 are described herein.
1. A composition comprising a compound selected from:
or a pharmaceutically acceptable salt thereof.
2. The composition of claim 1 , wherein the compound is:
or a pharmaceutically acceptable salt thereof.
3. The composition of claim 2 , further comprising the compound:
or a pharmaceutically acceptable salt thereof.
4. The composition of claim 1 , wherein the compound is:
or a pharmaceutically acceptable salt thereof.
5. The composition of claim 4 , further comprising the compound:
or a pharmaceutically acceptable salt thereof.
6. A composition comprising a compound selected from:
or a pharmaceutically acceptable salt thereof,
wherein the compound is obtained by a process comprising a step of treating a compound:
with hydroxylamine and a first base to form a compound:
wherein R 1 is selected from the group consisting of:
7. The composition of claim 6 , wherein the first base comprises a hydroxide ion.
8. The composition of claim 7 , wherein the first base is NaOH.
9. The composition of claim 6 , wherein the process further comprises a step of treating a compound:
with R 1 —X′, wherein X′ is halogen, and a second base to form the compound:
10. The composition of claim 9 , wherein the second base is NaH, K 2 CO 3 , or Cs 2 CO 3 .
11. The composition of claim 9 , wherein X′ is Cl or Br.
12. The composition of claim 6 , wherein the composition comprises:
or a pharmaceutically acceptable salt thereof,
wherein the compound is obtained by a process, comprising the step of treating the compound:
with hydroxylamine and a first base to form the compound:
13. The composition of claim 12 , wherein the process further comprises the step of treating the compound:
with R 1 —X′, wherein X′ is halogen, and a second base to form the compound:
14. The composition of claim 6 , wherein the composition comprises:
or a pharmaceutically acceptable salt thereof,
wherein the compound is obtained by a process, comprising the step of treating the compound:
with hydroxylamine and a first base to form the compound:
15. The composition of claim 14 , wherein the process further comprises the step of treating the compound:
with R 1 —X′, wherein X′ is halogen, and a second base to form the compound:
16. A composition comprising a first compound selected from:
and
a second compound:
17. The composition of claim 16 , wherein the first compound is:
18. The composition of claim 16 , wherein the first compound is: